

Table 3.5
Age-Specific SEER Incidence^a, by Age Group and Sex
By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
White, 2014-2018

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
All Sites Combined	27.3	26.6	41.3	43.5	56.3	78.4	77.4	134.4	103.1	204.0
1. LEUKEMIAS	4.3	2.6	3.5	2.5	3.4	2.7	4.2	3.3	5.3	4.0
1.1 Acute lymphoid leukemia	2.9	1.3	1.5	0.7	1.1	0.6	1.0	0.6	1.0	0.6
1.2 Acute myeloid leukemia	0.9	1.0	1.1	1.3	1.1	1.3	1.4	1.4	1.5	1.7
1.3 Chronic myeloid leukemia	0.3	0.2	0.6	0.3	0.9	0.6	1.2	0.9	1.4	1.0
1.4 Other and unspecified leukemias	0.2	0.1	0.2	0.2	0.4	0.2	0.5	0.3	1.4	0.6
2. LYMPHOMAS	6.2	5.2	7.6	6.8	8.1	7.4	9.1	7.7	11.8	8.4
2.1 Non-Hodgkin Lymphoma	2.7	1.5	3.0	2.1	3.9	3.0	5.3	4.3	8.4	5.6
2.2 Hodgkin Lymphoma	3.5	3.7	4.6	4.7	4.2	4.4	3.9	3.4	3.4	2.8
3. CNS, INTRACRANIAL, INTRASPINAL	2.6	2.1	2.5	2.0	3.5	2.8	4.4	3.3	4.7	3.7
3.1 Astrocytoma	1.5	1.2	1.6	1.1	2.0	1.6	2.6	1.8	2.8	2.2
3.1.1 Specified low-grade astrocytic tumors	0.8	0.7	0.4	0.3	0.4	0.2	0.3	0.3	0.3	0.3
3.1.2 Glioblastoma and anaplastic astrocytoma	0.4	0.3	0.8	0.4	1.0	0.9	1.6	1.1	1.9	1.4
3.1.3 Astrocytoma, NOS	0.3	0.3	0.4	0.3	0.6	0.4	0.6	0.4	0.6	0.5
3.2 Other glioma	0.5	0.4	0.5	0.5	0.9	0.8	1.2	1.0	1.3	1.0
3.3 Ependymoma	0.2	0.2	0.2	0.1	0.3	0.2	0.2	0.2	0.3	0.3
3.4 Medulloblastoma and other PNET	0.3	0.2	0.2	0.2	0.3	0.2	0.2	-	0.2	-
3.4.1 Medulloblastoma	0.2	-	0.1	0.1	0.2	0.1	0.2	-	0.1	-
3.4.2 Supratentorial PNET	-	-	-	-	-	-	-	-	-	-
3.5 Other specified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
3.6 Unspecified intracranial and intraspinal neoplasms	-	-	-	-	-	-	-	-	-	-
4. OSSEOUS & CHONDROMATOUS NEOPLASMS	2.1	1.2	1.2	0.9	0.8	0.8	0.8	0.7	1.0	0.9
4.1 Osteosarcoma	1.1	0.6	0.4	0.4	0.2	0.2	0.2	0.2	0.2	0.2
4.2 Chondrosarcoma	0.1	-	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3
4.3 Ewing tumor	0.8	0.5	0.6	0.3	0.2	0.2	0.2	0.2	0.2	0.2
4.4 Other specified and unspecified bone tumors	-	-	0.1	-	0.1	0.1	-	0.1	0.2	0.2
5. SOFT TISSUE SARCOMAS	1.6	1.4	1.7	1.6	2.6	2.2	3.5	2.8	4.0	3.4
5.1 Fibromatous neoplasms	0.3	0.2	0.3	0.4	0.5	0.7	0.7	0.8	0.8	0.9
5.2 Rhabdomyosarcoma	0.4	0.3	0.2	-	0.1	-	-	-	0.2	-
5.3 Other specified soft tissue sarcoma	0.9	0.9	1.2	1.1	2.0	1.4	2.7	1.9	3.0	2.5
5.3.1 Specified soft tissue sarcoma	0.7	0.7	0.9	0.8	1.6	1.0	2.2	1.4	2.5	1.9
5.3.1.1 Specified (excluding Kaposi sarcoma)	0.6	0.7	0.7	0.8	1.1	0.9	1.3	1.4	1.6	1.9
5.3.1.2 Kaposi sarcoma	-	-	0.1	-	0.5	-	0.9	-	0.9	-
5.3.2 Unspecified soft tissue sarcoma	0.3	0.2	0.3	0.2	0.4	0.4	0.5	0.5	0.5	0.5
6. GERM CELL AND TROPHOBLASTIC NEOPLASMS	5.0	0.9	14.0	1.0	18.3	1.1	18.7	1.0	15.4	0.5
6.1 Germ cell and trophoblastic neoplasms of gonads	4.4	0.8	13.3	0.8	17.8	0.8	18.2	0.5	15.2	0.2
6.2 Germ cell and trophoblastic neoplasms of nongonadal sites	0.7	0.1	0.7	0.2	0.5	0.3	0.5	0.4	0.2	0.3
6.2.1 Intracranial sites	0.5	-	0.3	-	0.2	-	-	-	-	-
6.2.2 Other nongonadal sites	0.2	-	0.4	0.2	0.4	0.3	0.4	0.4	0.2	0.3

Rates are per 100,000.

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.

Table 3.5 - continued
 Age-Specific SEER Incidence^a, by Age Group and Sex
 By Adapted Classification Scheme for Tumors of Adolescents and Young Adults^b
 White, 2014-2018

Site	Ages 15-19		Ages 20-24		Ages 25-29		Ages 30-34		Ages 35-39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
7. MELANOMA AND SKIN CARCINOMAS	0.8	1.5	2.2	4.9	4.6	9.9	9.0	16.5	12.6	19.5
7.1 Melanoma	0.8	1.4	2.1	4.9	4.6	9.9	8.9	16.4	12.4	19.4
7.2 Skin carcinomas	-	-	-	-	-	-	-	0.1	0.2	0.2
8. CARCINOMAS (excluding skin)	3.7	10.4	7.5	22.4	13.4	49.2	25.1	95.6	43.7	157.6
8.1 Thyroid carcinoma	1.2	6.7	3.0	14.2	4.7	22.5	7.0	30.8	9.4	37.2
8.2 Other carcinoma of head and neck	0.4	0.3	0.6	0.7	1.0	1.1	2.1	1.7	3.5	2.5
8.2.1 Nasopharyngeal carcinoma	-	-	0.1	-	-	-	0.1	-	0.2	-
8.2.2 Other sites in lip, oral cavity and pharynx	0.3	0.3	0.4	0.6	0.8	0.9	1.6	1.5	2.7	2.0
8.2.3 Nasal cavity, middle ear, sinuses, larynx, other ill-defined head/neck	-	-	-	-	0.1	0.2	0.3	0.2	0.6	0.4
8.3 Carcinoma of trachea, bronchus, and lung	0.1	-	0.3	0.3	0.5	0.6	1.0	1.1	2.0	2.5
8.4 Carcinoma of breast	-	-	-	1.4	-	9.8	-	29.4	0.2	62.8
8.5 Carcinoma of genitourinary tract	0.2	0.7	0.9	2.5	2.1	9.7	5.1	22.6	10.2	35.0
8.5.1 Carcinoma of kidney	-	0.2	0.5	0.5	1.3	1.2	3.7	2.9	7.2	5.1
8.5.2 Carcinoma of bladder	0.1	-	0.3	0.2	0.6	0.3	1.2	0.5	2.2	1.0
8.5.3 Carcinoma of gonads	-	0.3	-	0.8	-	1.6	-	2.6	-	4.4
8.5.4 Carcinoma of cervix and uterus	-	-	-	1.0	-	6.5	-	15.9	-	23.3
8.5.5 Carcinoma of other and ill-defined sites, genitourinary tract	-	-	-	-	-	0.2	0.2	0.7	0.8	1.2
8.6 Carcinoma of gastrointestinal tract	1.6	2.4	2.5	3.2	4.7	5.1	9.4	9.3	17.7	16.5
8.6.1 Carcinoma of colon and rectum	1.3	1.8	1.8	2.4	3.3	3.8	6.5	6.6	11.7	11.4
8.6.2 Carcinoma of stomach	-	-	0.2	0.2	0.4	0.4	1.0	0.9	2.1	1.9
8.6.3 Carcinoma of liver and intrahepatic bile ducts	0.2	0.2	0.2	0.2	0.3	0.2	0.5	0.4	0.6	0.6
8.6.4 Carcinoma of pancreas	-	0.3	0.1	0.3	0.2	0.5	0.7	0.8	1.4	1.5
8.6.5 Carcinoma of other and ill-defined sites, gastrointestinal tract	-	-	0.1	0.2	0.4	0.3	0.7	0.6	1.8	1.1
8.7 Carcinoma of other and ill-defined sites, NOS	-	0.1	0.2	0.2	0.3	0.4	0.5	0.5	0.8	1.0
8.7.1 Adrenocortical carcinoma	-	-	-	-	-	-	-	-	-	0.1
8.7.2 Carcinoma of other and ill-defined sites, NOS	-	-	0.2	0.1	0.2	0.3	0.5	0.4	0.7	0.9
9. MISCELLANEOUS SPECIFIED NEOPLASMS, NOS	0.9	1.1	1.0	1.0	1.3	2.0	2.2	3.0	3.8	4.8
9.1 Other pediatric and embryonal tumors, NOS	0.2	0.2	0.1	-	-	0.1	-	0.1	0.1	-
9.1.1 Wilms tumor	-	-	-	-	-	-	-	-	-	-
9.1.2 Neuroblastoma	-	-	-	-	-	-	-	-	-	-
9.1.3 Other pediatric and embryonal tumors, NOS	-	-	-	-	-	-	-	-	-	-
9.2 Other specified neoplasms, NOS	0.7	0.9	0.9	1.0	1.3	1.8	2.2	2.9	3.7	4.8
9.2.1 Paraganglioma and glomus tumors	-	-	-	-	-	-	-	-	-	-
9.2.2 Other specified gonadal tumors	-	0.1	-	-	-	0.1	-	0.2	-	0.3
9.2.3 Myeloma, mast cell, miscellaneous lymphoreticular neoplasms, NOS	0.3	0.2	0.3	0.2	0.3	0.3	0.6	0.4	1.2	1.1
9.2.4 Other specified neoplasms, NOS ^c	0.4	0.5	0.5	0.7	0.8	1.4	1.4	2.2	2.4	3.3
10. UNSPECIFIED MALIGNANT NEOPLASMS	-	-	0.1	0.2	0.2	0.3	0.3	0.5	0.6	1.0

Rates are per 100,000.

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b Adapted from: RD Barr, EJ Holowaty, JM Birch. Classification Scheme for tumors diagnosed in adolescents and young adults. Cancer. 106:7; 1425-1430. (Restricted to malignant tumors and updated based on ICD-O-3 definitions).

^c Myeloproliferative disorders and myelodysplastic syndromes were first reported effective January 1, 2001 with the implementation of ICD-O 3.

- Statistic could not be calculated. Rate based on less than 16 cases for the time interval.